Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: A meta-analysis

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Jin, Fei ^a   Qu, Li Shuai ^a   Shen, Xi Zhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL LIVER CIRRHOSIS; ARTICLE; CANCER RISK; DNA POLYMORPHISM; EUROPE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; HEMOCHROMATOSIS GENE; HUMAN; LIVER CELL CARCINOMA; MISSENSE MUTATION; PRIORITY JOURNAL; ALCOHOLISM; CAUCASIAN; GENETIC POLYMORPHISM; GENETICS; LIVER TUMOR; META ANALYSIS; MUTATION;

HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ALCOHOLISM; CARCINOMA, HEPATOCELLULAR; EUROPEAN CONTINENTAL ANCESTRY GROUP; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MUTATION; POLYMORPHISM, GENETIC;

EID: 77950200986     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-18     Document Type: Article

References (37)

1. Hereditary haemochromatosis. CQ Edwards MM Dadone MH Skolnick JP Kushner, Clin Haematol 1982 11 2 411 435 7042159
2. Diagnosis and management of hemochromatosis. AS Tavill, Hepatology 2001 33 5 1321 1328 10.1053/jhep.2001.24783 11343262
3. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. C Niederau R Fischer A Sonnenberg W Stremmel HJ Trampisch G Strohmeyer, N Engl J Med 1985 313 20 1256 1262 4058506
4. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. S Fargion C Mandelli A Piperno B Cesana AL Fracanzani M Fraquelli PA Bianchi G Fiorelli D Conte, Hepatology 1992 15 4 655 659 10.1002/hep.1840150417 1312985
5. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. JN Feder A Gnirke W Thomas Z Tsuchihashi DA Ruddy A Basava F Dormishian R Domingo Jr MC Ellis A Fullan LM Hinton NL Jones BE Kimmel GS Kronmal P Lauer VK Lee DB Loeb FA Mapa E McClelland NC Meyer GA Mintier N Moeller T Moore E Morikang CE Prass L Quintana SM Starnes RC Schatzman KJ Brunke DT Drayna NJ Risch BR Bacon RK Wolff, Nat Genet 1996 13 4 399 408 10.1038/ng0896-399 8696333
6. [Association of mutations of HFE gene and hepatocellular carcinoma following chronic hepatitis B]. WJ Shi H Chen B Zhou J Cheng, Zhonghua Gan Zang Bing Za Zhi 2005 13 9 682 684 16174459
7. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. E Lauret M Rodriguez S Gonzalez A Linares A Lopez-Vazquez J Martinez-Borra L Rodrigo C Lopez-Larrea, Am J Gastroenterol 2002 97 4 1016 1021 10.1111/j.1572-0241.2002.05553.x 12003382
8. Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma. S Fargion MA Stazi AL Fracanzani M Mattioli M Sampietro D Tavazzi C Bertelli V Patriarca C Mariani G Fiorelli, Blood Cells Mol Dis 2001 27 2 505 511 10.1006/bcmd.2001.0411 11500061
9. Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study. G Willis V Bardsley IW Fellows R Lonsdale JZ Wimperis BA Jennings, BMC Gastroenterol 2005 5 17 10.1186/1471-230X-5-17 15929796
10. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. C Hellerbrand A Poppl A Hartmann J Scholmerich G Lock, Clin Gastroenterol Hepatol 2003 1 4 279 284 10.1016/S1542-3565(03)00132-0 15017669
11. Mutations of the HFE gene in patients with hepatocellular carcinoma. E Cauza M Peck-Radosavljevic H Ulrich-Pur C Datz M Gschwantler M Schoniger-Hekele F Hackl C Polli S Rasoul-Rockenschaub C Muller F Wrba A Gangl P Ferenci, Am J Gastroenterol 2003 98 2 442 447 10.1111/j.1572-0241.2003.07222.x 12591066
12. Incidence of liver disease in people with HFE mutations. G Willis JZ Wimperis R Lonsdale IW Fellows MA Watson LM Skipper BA Jennings, Gut 2000 46 3 401 404 10.1136/gut.46.3.401 10673304
13. Prevalence of common HFE and SERPINA1 mutations in patients with hepatocellular carcinoma in a Moroccan population. S Ezzikouri AE El Feydi L El Kihal R Afifi M Benazzouz M Hassar A Chafik P Pineau S Benjelloun, Arch Med Res 2008 39 2 236 241 10.1016/j.arcmed.2007.09.006 18164971
14. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. P Nahon A Sutton P Rufat M Ziol G Thabut PO Schischmanoff D Vidaud N Charnaux P Couvert N Ganne-Carrie JC Trinchet L Gattegno M Beaugrand, Gastroenterology 2008 134 1 102 110 10.1053/j.gastro.2007. 10.038 18061182
15. [The H63D mutation in the HFE gene is related to the risk of hepatocellular carcinoma]. P Ropero O Briceno G Lopez-Alonso JA Agundez FA Gonzalez Fernandez F Garcia-Hoz A Villegas Martinez M Diaz-Rubio JM Ladero, Rev Esp Enferm Dig 2007 99 7 376 381 10.4321/S1130-01082007000700002 17973580
16. Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. V Boige L Castera N de Roux N Ganne-Carrie B Ducot G Pelletier M Beaugrand C Buffet, Gut 2003 52 8 1178 1181 10.1136/gut.52.8.1178 12865278
17. Mutations of the HFE gene and the risk of hepatocellular carcinoma. O Racchi R Mangerini D Rapezzi GF Gaetani MT Nobile A Picciotto AM Ferraris, Blood Cells Mol Dis 1999 25 5-6 350 353 10.1006/bcmd.1999.0263 10660482
18. Analysis of haemochromatosis gene mutations in a population from the Mediterranean Basin. S Campo T Restuccia D Villari G Raffa D Cucinotta G Squadrito T Pollicino G Raimondo, Liver 2001 21 4 233 236 10.1034/j.1600-0676. 2001.021004233.x 11454185
19. Penetrance of 845G - > A (C282Y) HFE hereditary haemochromatosis mutation in the USA. E Beutler VJ Felitti JA Koziol NJ Ho T Gelbart, Lancet 2002 359 9302 211 218 10.1016/S0140-6736(02)07447-0 11812557
20. SNP selection for genes of iron metabolism in a study of genetic modifiers of hemochromatosis. CC Constantine LC Gurrin CE McLaren M Bahlo GJ Anderson CD Vulpe SM Forrest KJ Allen DM Gertig, BMC Med Genet 2008 9 18 10.1186/1471-2350-9-18 18366708
21. Quantitative synthesis in systematic reviews. J Lau JP Ioannidis CH Schmid, Ann Intern Med 1997 127 9 820 826 9382404
22. Heterogeneity testing in meta-analysis of genome searches. E Zintzaras JP Ioannidis, Genet Epidemiol 2005 28 2 123 137 10.1002/gepi.20048 15593093
23. Quantifying heterogeneity in a meta-analysis. JP Higgins SG Thompson, Stat Med 2002 21 11 1539 1558 10.1002/sim.1186 12111919
24. Bias in meta-analysis detected by a simple, graphical test. M Egger G Davey Smith M Schneider C Minder, BMJ 1997 315 7109 629 634 9310563
25. Operating characteristics of a rank correlation test for publication bias. CB Begg M Mazumdar, Biometrics 1994 50 4 1088 1101 10.2307/2533446 7786990
26. Power and sample size calculations for studies involving linear regression. WD Dupont WD Plummer Jr, Control Clin Trials 1998 19 6 589 601 10.1016/S0197-2456(98)00037-3 9875838
27. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. S Wacholder S Chanock M Garcia-Closas L El Ghormli N Rothman, J Natl Cancer Inst 2004 96 6 434 442 15026468
28. Estimating the population attributable risk for multiple risk factors using case-control data. P Bruzzi SB Green DP Byar LA Brinton C Schairer, Am J Epidemiol 1985 122 5 904 914 4050778
29. Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients. M Pirisi P Toniutto A Uzzau C Fabris C Avellini C Scott L Apollonio CA Beltrami F Bresadola, Cancer 2000 89 2 297 302 10.1002/1097-0142(20000715)89:2<297::AID-CNCR14>3.0.CO;2-N 10918159
30. Interaction between haemochromatosis and transferrin receptor genes in hepatocellular carcinoma. LE Beckman I Hagerstrand R Stenling GF Van Landeghem L Beckman, Oncology 2000 59 4 317 322 10.1159/000012189 11096344
31. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. JN Feder DM Penny A Irrinki VK Lee JA Lebron N Watson Z Tsuchihashi E Sigal PJ Bjorkman RC Schatzman, Proc Natl Acad Sci USA 1998 95 4 1472 1477 10.1073/pnas.95.4.1472 9465039
32. Long-term survival in patients with hereditary hemochromatosis. C Niederau R Fischer A Purschel W Stremmel D Haussinger G Strohmeyer, Gastroenterology 1996 110 4 1107 1119 10.1053/gast.1996.v110.pm8613000 8613000
33. Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention. JE Haddow GE Palomaki M McClain W Craig, J Med Screen 2003 10 1 11 13 10.1258/ 096914103321610743 12790309
34. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. A Asberg K Hveem K Thorstensen E Ellekjter K Kannelonning U Fjosne TB Halvorsen HB Smethurst E Sagen KS Bjerve, Scand J Gastroenterol 2001 36 10 1108 1115 10.1080/003655201750422747 11589387
35. Iron-overload-related disease in HFE hereditary hemochromatosis. KJ Allen LC Gurrin CC Constantine NJ Osborne MB Delatycki AJ Nicoll CE McLaren M Bahlo AE Nisselle CD Vulpe GJ Anderson MC Southey GG Giles DR English JL Hopper JK Olynyk LW Powell DM Gertig, N Engl J Med 2008 358 3 221 230 10.1056/NEJMoa073286 18199861
36. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. C Ellervik H Birgens A Tybjaerg-Hansen BG Nordestgaard, Hepatology 2007 46 4 1071 1080 10.1002/hep.21885 17828789
37. Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow up study. N Ganne-Carrie C Christidis C Chastang M Ziol F Chapel F Imbert-Bismut JC Trinchet C Guettier M Beaugrand, Gut 2000 46 2 277 282 10.1136/gut.46.2.277 10644325